Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions

Journal of Biological Chemistry

Volumn 288, Issue 2, 2013, Pages 1409-1419

  Zhong, Xiaotian ^a   Kieras, Elizabeth ^a   Sousa, Eric ^a   D'Antona, Aaron ^a   Baber, J Christian ^a   He, Tao ^a   Desharnais, Joel ^a   Wood, Lauren ^a   Luxenberg, Deborah ^a   Stahl, Mark ^a   Kriz, Ronald ^a   Lin, Laura ^a   Somers, Will ^a   Fitz, Lori J ^a   Wright, Jill F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITIES; BIOLOGICAL PROCESS; CELL-BASED ASSAYS; EXPERIMENTAL EVIDENCE; EXTRACELLULAR SECRETION; FUSION PROTEINS; HEAVY CHAIN; LIGHT CHAIN; MAMMALIAN CELLS; N-TERMINALS; O-LINKED; OPEN READING FRAME; POST-TRANSLATIONAL MODIFICATIONS; PROTEIN BIOSYNTHESIS; SECRETORY PATHWAYS; SITE DIRECTED MUTAGENESIS; THERAPEUTIC PROTEIN;

AMINO ACIDS; ANTIBODIES; BINDING ENERGY; BIOCHEMISTRY; BIOSYNTHESIS; PEPTIDES; SPECTROSCOPIC ANALYSIS;

SCAFFOLDS (BIOLOGY);

ANTIBODY; GLYCAN; HYBRID PROTEIN; INETRELUKIN 17A ANTIBODY; INETRELUKIN 22 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; PEPTIDE; POLYGLUTAMIC ACID; Q G HC PROTEIN; Q G LC PROTEIN; Q G TETRAVALENT PROTEIN; Q G6 HC PROTEIN; Q G6 LC PROTEIN; Q G6 TETRAVALENT PROTEIN; Q GSE12 HC PROTEIN; Q GSE12 LC PROTEIN; Q GSE12 TETRAVALENT PROTEIN; Q GSE21 TETRAVALENT PROTEIN; THREONINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; DRUG STRUCTURE; EMBRYO; GENETIC ENGINEERING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRROLIDONECARBOXYLIC ACID;

MAMMALIA;

EID: 84872361983     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.417717     Document Type: Article

References (54)

1. Wurm, F. M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393-1398
2. Omasa, T., Onitsuka, M., and Kim, W. D. (2010) Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr. Pharm. Biotechnol. 11, 233-240
3. Carter, P. J. (2006) Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357
4. Leader, B., Baca, Q. J., and Golan, D. E. (2008) Protein therapeutics. A summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21-39
5. Leavy, O. (2010) Therapeutic antibodies. Past, present and future. Nat. Rev. Immunol. 10, 297
6. Kelley, W. S. (1996) Therapeutic peptides. The devil is in the details. Biotechnology 14, 28-31
7. Bray, B. L. (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2, 587-593
8. Stone, G. W., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., Pocock, S. J., Ware, J. H., Feit, F., Colombo, A., Aylward P. E., Cequier, A. R., Darius, H., Desmet, W., Ebrahimi, R., Hamon, M., Rasmussen, L. H., Rupprecht, H. J., Hoekstra, J., Mehran, R., Ohman, E. M., and ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355, 2203-2216 (Pubitemid 44791162)
9. Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., Porter, L., and DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes. A randomised, open-label, non-inferiority study. Lancet 372, 1240-1250
10. McGregor, D. P. (2008) Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8, 616-619
11. Zuraw, B., Yasothan, U., and Kirkpatrick, P. (2010) Ecallantide. Nat. Rev. Drug Discov. 9, 189-190
12. Cohn, C. S., and Bussel, J. B. (2009) Romiplostim. A second-generation thrombopoietin agonist. Drugs Today 45, 175-188
13. Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A. M., Froissart, M., and Eckardt, K. U. (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med. 361, 1848-1855
14. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., and Dower, W. J. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-464
15. Fishburn, C. S. (2008) The pharmacology of PEGylation. Balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97, 4167-4183
16. Bendele, A., Seely, J., Richey, C., Sennello, G., and Shopp, G. (1998) Short communication. Renal tubular vacuolation in animals treated with polyethylene- glycol-conjugated proteins. Toxicol. Sci. 42, 152-157 (Pubitemid 28211143)
17. Sroda, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., and Sikorski, A. F. (2005) Repeated injections of PEG-PE liposomes generate anti- PEG antibodies. Cell Mol. Biol. Lett. 10, 37-47 (Pubitemid 40559058)
18. Huang, C. (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol. 20, 692-699
19. Subramanian, G. M., Fiscella, M., Lamousé-Smith, A., Zeuzem, S., and McHutchison, J. G. (2007) Albinterferon α-2b. A genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25, 1411-1419 (Pubitemid 350233139)
20. Schellenberger, V., Wang, C. W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., Cleland, J. L., Silverman, J., and Stemmer, W. P. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186-1190
21. Rader, C., Turner, J. M., Heine, A., Shabat, D., Sinha, S. C., Wilson, I. A., Lerner, R. A., and Barbas, C. F. (2003) A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J. Mol. Biol. 332, 889-899 (Pubitemid 37101375)
22. Doppalapudi, V. R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., Desharnais, J., Hagen, C., Levin, N. J., Shields, M. J., Parish, M., Murphy, R. E., Del Rosario, J., Oates, B. D., Lai, J. Y., Matin, M. J., Ainekulu, Z., Bhat, A., Bradshaw, C. W. Woodnutt, G., Lerner, R. A., and Lappe, R. W. (2010) Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 107, 22611-22616
23. Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S. A., Akanbi, M. H., and Moll, G. N. (2010) To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods 61, 210-218
24. Fouser, L. A., Wright, J. F., Dunussi-Joannopoulos, K., and Collins, M. (2008) Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol. Rev. 226, 87-102
25. Miossec, P., Korn, T., and Kuchroo, V. K. (2009) Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898
26. Korn, T., Bettelli, E., Oukka, M., and Kuchroo, V. K. (2009) IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517
27. Liang, S. C., Tan, X. Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., and Fouser, L. A. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271-2279 (Pubitemid 44498362)
28. Ma, H. L., Liang, S., Li, J., Napierata, L., Brown, T., Benoit, S., Senices, M., Gill, D., Dunussi-Joannopoulos, K., Collins, M., Nickerson-Nutter, C., Fouser, L. A., and Young, D. A. (2008) IL-22 is required for Th17 cellmediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118, 597-607 (Pubitemid 351206549)
29. Myszka, D. G. (1999) Improving biosensor analysis. J. Mol. Recognit. 12, 279-284
30. Ebbinghaus, S., Kim, S. J., Heyden, M., Yu, X., Heugen, U., Gruebele, M., Leitner, D. M., and Havenith, M. (2007) An extended dynamical hydration shell around proteins. Proc. Natl. Acad. Sci. U.S.A. 104, 20749-20752
31. Gerhardt, S., Abbott, W. M., Hargreaves, D., Pauptit, R. A., Davies, R. A., Needham, M. R., Langham, C., Barker, W., Aziz, A., Snow, M. J., Dawson, S., Welsh, F., Wilkinson, T., Vaugan, T., Beste, G., Bishop, S., Popovic, B., Rees, G., Sleeman, M., Tuske, S. J., Coales, S. J., Hamuro, Y., and Russell, C. (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J. Mol. Biol. 394, 905-921
32. Liang, S. C., Nickerson-Nutter, C., Pittman, D. D., Carrier, Y., Goodwin, D. G., Shields, K. M., Lambert, A. J., Schelling, S. H., Medley, Q. G., Ma, H. L., Collins, M., Dunussi-Joannopoulos, K., and Fouser, L. A. (2010) IL-22 induces an acute-phase response. J. Immunol. 185, 5531-5538
33. Sonnenberg, G. F., Fouser, L. A., and Artis, D. (2010) Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv. Immunol. 107, 1-29
34. Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J. M., Diepolder, H., Marquardt, A., Jagla, W., Popp, A., Leclair, S., Herrmann, K., Seiderer, J., Ochsenkühn, T., Göke, B., Auernhammer, C. J., and Dambacher, J. (2006) IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838
35. Liang, S. C., Long, A. J., Bennett, F., Whitters, M. J., Karim, R., Collins, M., Goldman, S. J., Dunussi-Joannopoulos, K., Williams, C. M., Wright, J. F., and Fouser, L. A. (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 179, 7791-7799
36. Dick, L. W., Jr., Kim, C., Qiu, D., and Cheng, K. C. (2007) Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol. Bioeng. 97, 544-553 (Pubitemid 46848069)
37. Liu, Y. D., Goetze, A. M., Bass, R. B., and Flynn, G. C. (2011) N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J. Biol. Chem. 286, 11211-11217
38. Van den Steen, P., Rudd, P. M., Dwek, R. A., and Opdenakker, G. (1998) Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol. 33, 151-208 (Pubitemid 28334620)
39. Hanisch, F. G., Jovanovic, M., and Peter-Katalinic, J. (2001) Glycoprotein identification and localization of O-glycosylation sites by mass spectrometric analysis of deglycosylated/alkylaminylated peptide fragments. Anal. Biochem. 290, 47-59 (Pubitemid 32182269)
40. Peschen, D., Li, H. P., Fischer, R., Kreuzaler, F., and Liao, Y. C. (2004) Fusion proteins comprising a Fusarium-specific antibody linked to antifungal peptides protect plants against a fungal pathogen. Nat. Biotechnol. 22, 732-738 (Pubitemid 38702830)
41. Smith, G. P. (1985) Filamentous fusion phage. Novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317
42. Cull, M. G., Miller, J. F., and Schatz, P. J. (1992) Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor. Proc. Natl. Acad. Sci. U.S.A. 89, 1865-1869
43. Mattheakis, L. C., Bhatt, R. R., and Dower, W. J. (1994) An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. U.S.A. 91, 9022-9026
44. Zahnd, C., Amstutz, P., and Pluckthun, A. (2007) Ribosome display. Selecting and evolving proteins in vitro that specifically bind to a target. Nat. Methods 4, 269-279 (Pubitemid 46358879)
45. Roberts, R. W., and Szostak, J. W. (1997) RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. U.S.A. 94, 12297-12302 (Pubitemid 27492522)
46. Huang, B. C., and Liu, R. (2007) Comparison of mRNA-display-based selections using synthetic peptide and natural protein libraries. Biochemistry 46, 10102-10112
47. Odegrip, R., Coomber, D., Eldridge, B., Hederer, R., Kuhlman, P. A., Ullman, C., FitzGerald, K., and McGregor, D. (2004) CIS display. In vitro selection of peptides from libraries of protein-DNA complexes. Proc. Natl. Acad. Sci. U.S.A. 101, 2806-2810 (Pubitemid 38327692)
48. Yonezawa, M., Doi, N., Higashinakagawa, T., and Yanagawa, H. (2004) DNA display of biologically active proteins for in vitro protein selection. J. Biochem. 135, 285-288 (Pubitemid 38506753)
49. Hagemeyer, C. E., von Zur Muhlen, C., von Elverfeldt, D., and Peter, K. (2009) Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb. Haemost. 101, 1012-1019
50. Hudson, P. J., and Kortt, A. A. (1999) High avidity scFv multimers. Diabodies and triabodies. J. Immunol. Methods 231, 177-189 (Pubitemid 30394733)
51. Kipriyanov, S. M. (2009) Generation of bispecific and tandem diabodies. Methods Mol. Biol. 562, 177-193
52. Bostrom, J., Yu, S. F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., and Fuh, G. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614
53. Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R. R., Santora, L., Davis-Taber, R., Kunes, Y., Fung, E., Schwartz, A., Sakorafas, P., Gu, J., Tarcsa, E., Murtaza, A., and Ghayur, T. (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25, 1290-1297 (Pubitemid 350076510)
54. Walsh, G., and Jefferis, R. (2006) Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24, 1241-1252 (Pubitemid 44564769)